Engineered cpl-1 endolysin for dual-action treatment of central nervous system bacterial infections: killing antibiotic-resistant bacteria and neutralizing released toxins

Abstract The global rise of antimicrobial resistance and the limited efficacy of current therapies against toxin-mediated pathology highlight the urgent need for innovative anti-infective strategies. In pneumococcal meningitis, a leading cause of mortality and long-term neurological sequelae, treatment is complicated not only by antibiotic-resistant Streptococcus pneumoniae (the pneumococcus) but also by the release of pneumolysin (Ply), a pore-forming toxin that drives neuronal damage and neuroinflammation. Here, we present the design and preclinical characterization of an endolysin-based dual-action fusion protein, using cpl-1 as a proof-of-concept scaffold, that combines bactericidal activity with toxin-neutralizing properties for infectious disease treatment. We engineered a chimeric protein by fusing a Mannose Receptor C-type 1 (MRC-1)-derived anti-Ply peptide to the N-terminus of the well-characterized pneumococcal endolysin cpl-1. The engineered endolysin demonstrated potent bactericidal activity against a broad panel of pneumococcal strains, including antibiotic-resistant and non-vaccine serotypes, producing an approximately 2-log10 CFU/mL reduction in human blood and approximately 60% reduction in turbidity in human cerebrospinal fluid. Importantly, the fusion protein could bind Ply reducing infection-associated neuronal cytotoxicity by more than 25% compared with cpl-1 in human neuronal cell models, addressing a key limitation of conventional bactericidal antibiotic therapies which can exacerbate toxin release. Mechanistically, incorporation of the MRC-1-derived peptide reduced toxin-induced damage, enabling simultaneous bacterial clearance and toxin neutralization. Furthermore, the fusion protein also demonstrated the ability to cross the blood-brain barrier in vivo; in a mouse model of penicillin-resistant invasive pneumococcal disease, the combination treatment, thanks to Ply-binding peptide (PBP)-cpl-1’s synergy with standard-of-care antibiotics, resulted in approximately 60% survival following a single dose and 65% survival following two doses, compared with 0% survival in untreated controls, together with delayed disease progression and reduced inflammatory responses in the brain and peripheral tissues. Collectively, our findings position engineered endolysins as a promising next-generation anti-infective strategy for the treatment of severe infections, particularly in anatomically protected sites such as the central nervous system, where current antibiotic therapies often show limited efficacy.

Authors

Publication Details

Journal
Molecular Medicine
Published
2026-11-14
DOI
https://doi.org/10.1186/s10020-026-01697-w
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Engineered cpl-1 endolysin for dual-action treatment of central nervous system bacterial infections: killing antibiotic-resistant bacteria and neutralizing released toxins

Adit B. Alreja, Daniel Kemboi, Niels Vander Elst, Federico Iovino et al.
Molecular Medicine
Bacteriophages and microbial interactions
article

Engineered cpl-1 endolysin for dual-action treatment of central nervous system bacterial infections: killing antibiotic-resistant bacteria and neutralizing released toxins

Adit B. Alreja, Daniel Kemboi, Niels Vander Elst, Federico Iovino, Kristine Farmen, Daniel C Nelson, Lotte Merlijn, Valentina Mocci, Clara Caceffo
article en

Abstract

Abstract The global rise of antimicrobial resistance and the limited efficacy of current therapies against toxin-mediated pathology highlight the urgent need for innovative anti-infective strategies. In pneumococcal meningitis, a leading cause of mortality and long-term neurological sequelae, treatment is complicated not only by antibiotic-resistant Streptococcus pneumoniae (the pneumococcus) but also by the release of pneumolysin (Ply), a pore-forming toxin that drives neuronal damage and neuroinflammation. Here, we present the design and preclinical characterization of an endolysin-based dual-action fusion protein, using cpl-1 as a proof-of-concept scaffold, that combines bactericidal activity with toxin-neutralizing properties for infectious disease treatment. We engineered a chimeric protein by fusing a Mannose Receptor C-type 1 (MRC-1)-derived anti-Ply peptide to the N-terminus of the well-characterized pneumococcal endolysin cpl-1. The engineered endolysin demonstrated potent bactericidal activity against a broad panel of pneumococcal strains, including antibiotic-resistant and non-vaccine serotypes, producing an approximately 2-log10 CFU/mL reduction in human blood and approximately 60% reduction in turbidity in human cerebrospinal fluid. Importantly, the fusion protein could bind Ply reducing infection-associated neuronal cytotoxicity by more than 25% compared with cpl-1 in human neuronal cell models, addressing a key limitation of conventional bactericidal antibiotic therapies which can exacerbate toxin release. Mechanistically, incorporation of the MRC-1-derived peptide reduced toxin-induced damage, enabling simultaneous bacterial clearance and toxin neutralization. Furthermore, the fusion protein also demonstrated the ability to cross the blood-brain barrier in vivo; in a mouse model of penicillin-resistant invasive pneumococcal disease, the combination treatment, thanks to Ply-binding peptide (PBP)-cpl-1’s synergy with standard-of-care antibiotics, resulted in approximately 60% survival following a single dose and 65% survival following two doses, compared with 0% survival in untreated controls, together with delayed disease progression and reduced inflammatory responses in the brain and peripheral tissues. Collectively, our findings position engineered endolysins as a promising next-generation anti-infective strategy for the treatment of severe infections, particularly in anatomically protected sites such as the central nervous system, where current antibiotic therapies often show limited efficacy.

Molecular Medicine
Bacteriophages and microbial interactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon